Compare PLSE & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | PHVS |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.7B |
| IPO Year | 2016 | 2021 |
| Metric | PLSE | PHVS |
|---|---|---|
| Price | $14.60 | $24.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $22.00 | ★ $39.44 |
| AVG Volume (30 Days) | 199.0K | ★ 266.8K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $86,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,002.94 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $11.51 |
| 52 Week High | $25.00 | $29.80 |
| Indicator | PLSE | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 53.11 | 48.62 |
| Support Level | $13.17 | $23.62 |
| Resistance Level | $14.91 | $26.77 |
| Average True Range (ATR) | 0.83 | 1.57 |
| MACD | 0.10 | -0.16 |
| Stochastic Oscillator | 54.48 | 28.38 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.